Loading…
← CockpitCompetitor Analysis › 688575.SS Shenzhen YHLO Biotech Co. Ltd. Class AOpen in the cockpit ↗

Shenzhen YHLO Biotech Co. Ltd. Class A688575.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum leader 88
Mkt cap
$882M
US dollars, full cap
Free float
42%
of shares outstanding
$/day
$16.8M
20-day average traded
Fwd P/E
30.7×
forward earnings
ROIC−WACC
+5.0 pp
WACC 6.6%
Hurdle
-11 pp
Req g minus delivered
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥10.34
1D-2.0%
1W-4.9%
1M-1.1%
3M+7.7%
6M-15.6%
YTD-27.2%
1Y-31.2%
ATR %4.0%
52w lowhigh39.2% off high

What Shenzhen YHLO Biotech does

Employees: 1,664

Shenzhen YHLO Biotech at a glance

Size Shenzhen YHLO Biotech (688575.SS) is a China Health Care company (Medical Specialties) with a market value of $882M, the 2401st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.34 on 18 Nov 2026.

Performance Over six months the shares fell 15.6%, against -13.6% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue grew 2.9% over the last twelve months (peer median +7.3%); the operating margin is 12.1% (peer median 8.8%).

Valuation It trades at 30.7× forward earnings against a peer median of 24.1× (6th most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -11 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 5.0 points above its cost of capital (6.6% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 87688575.SS 85
Six months, rebased to 100: Shenzhen YHLO Biotech against the median of its 20 peers (local-currency closes).

Shenzhen YHLO Biotech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.95BCN¥1.80BCN¥2.00BCN¥2.04BCN¥3.95B
Revenue growth—-10%-2%-48%—
Gross profitCN¥1.31BCN¥893MCN¥1.08BCN¥995MCN¥2.00B
EBITDAn/aCN¥482MCN¥589MCN¥422MCN¥1.27B
Net incomeCN¥106MCN¥23.3MCN¥302MCN¥355MCN¥1.01B
Free cash flowCN¥211MCN¥71.5M-CN¥57.9M-CN¥727MCN¥1.02B
Capital expenditureCN¥541MCN¥359MCN¥593MCN¥663MCN¥565M
Total debtCN¥888MCN¥921MCN¥940MCN¥587MCN¥490M

Quarterly statements and history in the cockpit →

Shenzhen YHLO Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%688767688626301580688277BVS002658AORT688656KURN30160236001187KIDS2906507780SFL688068MCAP688575.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shenzhen YHLO Biotech is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×688767688626301580BVS002658AORT688656KURN360060336711877780SFL688575.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shenzhen YHLO Biotech is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%301580BVS00265868865630160236006033671187290650SFLMCAP688575.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shenzhen YHLO Biotech is the large dot.

Shenzhen YHLO Biotech competitors and peer comparison

How Shenzhen YHLO Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shenzhen YHLO Biotech against its 20 peers (data as of 18 Nov 2026)
Measure688575.SSPeer medianRank in peer set
1-month return-1.1%-8.0%7th highest of 21
6-month return-15.6%-13.6%10th lowest of 21
Distance from 52-week high-39.2%-43.3%9th highest of 21
Revenue growth (TTM)+2.9%+7.3%7th lowest of 21
Operating margin12.1%8.8%7th highest of 21
Forward P/E30.7×24.1×6th most expensive of 15
Growth the price implies (Req g, 7 yrs)2.0%9.3%5th least demanding of 13
Growth delivered (Del g)+12.7%+11.7%5th highest of 13
Hurdle (Req g minus delivered)-10.6 pp-3.7 pp5th least demanding of 13
ROIC minus cost of capital+5.0 pp+1.5 pp5th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shenzhen YHLO Biotech 688575.SSChina$882M-16%+3%12%30.7×2.0%+12.7%
Hangzhou Biotest Biotech 688767.SSChina$878M-12%-4%3%37.0×n/an/a
Xiangyu Medical 688626.SSChina$877M-38%0%4%56.2×n/an/a
Aidite (Qinhuangdao) Technology 301580.SZChina$888M-12%+17%18%26.2×19.3%+23.3%
Tinavi Medical Technologies 688277.SSChina$872M-36%-2%-59%n/an/an/a
Bioventus BVSUnited States$895M-3%+4%10%13.0×7.5%+12.1%
Beijing SDL Technology 002658.SZChina$864M-34%-13%9%22.4×16.8%+2.9%
Artivion AORTUnited States$905M-18%+14%5%383.6×n/an/a
HOB Biotech 688656.SSChina$858M-33%+6%7%166.9×37.6%+12.4%
Kuros Biosciences KURN.SWSwitzerland$907M-12%+41%6%70.5×n/an/a
Shantou Institute of Ultrasonic Instruments 301602.SZChina$858M-25%+4%30%n/a11.1%+4.6%
Modern Dental 3600.HKHong Kong$844M+24%+12%22%8.5×-7.1%+11.3%
Cisen Pharmaceutical 603367.SSChina$843M-15%-6%8%7.9×-14.6%-1.3%
Cofoe Medical Technology 1187.HKHong Kong$836M-11%+40%10%13.1×-6.4%+6.6%
OrthoPediatrics KIDSUnited States$826M+71%+16%-8%n/an/an/a
L&C BIO 290650.KSSouth Korea$943M-37%+65%20%n/a32.6%+21.0%
Menicon 7780.TJapan$944M+26%+6%9%20.9×n/an/a
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%n/a35.6%+17.1%
Safilo SFL.MIItaly$953M+42%-4%9%15.8×1.3%+4.7%
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%n/an/an/a
MedCap MCAP.STSweden$811M-4%+17%15%25.8×2.7%+20.9%

Questions

Which companies are Shenzhen YHLO Biotech's closest peers?
The cockpit's peer set: Hangzhou Biotest Biotech (688767.SS), Xiangyu Medical (688626.SS), Aidite (Qinhuangdao) Technology (301580.SZ), Tinavi Medical Technologies (688277.SS), Bioventus (BVS), Beijing SDL Technology (002658.SZ), Artivion (AORT), HOB Biotech (688656.SS).
Is Shenzhen YHLO Biotech expensive compared with its peers?
On forward p/e it trades at 30.7× against a peer median of 24.1×, 6th most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -11 pp: the price already allows for a slowdown.
How has Shenzhen YHLO Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned -15.6% against -13.6% for the median peer; over one year -31.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.